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Abstract
Background: Antibiotics are commonly administered to hospitalized patients with infiltrates for possible bacterial
pneumonia, often leading to unnecessary treatment and increasing the risk for resistance emergence. Therefore, we
performed a study to determine if an enhanced antibiotic de-escalation practice could improve antibiotic utilization
in mechanically ventilated patients with suspected pneumonia cared for in an academic closed intensive care unit (ICU).
Methods: This was a prospective cross-over trial comparing routine antibiotic management (RAM) and enhanced
antimicrobial de-escalation (EAD) performed within two medical ICUs (total 34 beds) at Barnes-Jewish Hospital, an
academic referral center. Patients in the EAD group had their antibiotic orders and microbiology results reviewed daily by
a dedicated team comprised of a second-year critical care fellow, an ICU attending physician and an ICU pharmacist.
Antibiotic de-escalation recommendations were made when appropriate based on microbiologic test results and clinical
response to therapy.
Results: There were 283 patients evaluable, with suspected pneumonia requiring mechanical ventilation: 139 (49.1%)
patients in the RAM group and 144 (50.9%) in the EAD group. Early treatment failure based on clinical deterioration
occurred in 33 (23.7%) and 40 (27.8%) patients, respectively (P = 0.438). In the remaining patients, antimicrobial
de-escalation occurred in 70 (66.0%) and 70 (67.3%), respectively (P = 0.845). There was no difference between
groups in total antibiotic days ((median (interquartile range)) 7.0 days (4.0, 9.0) versus 7.0 days (4.0, 8.8) (P = 0.
616)); hospital mortality (25.2% versus 35.4% (P = 0.061)); or hospital duration (12.0 days (6.0, 20.0) versus 11.0 days
(6.0, 22.0) (P = 0.918).
Conclusions: The addition of an EAD program to a high-intensity daytime staffing model already practicing a
high-level of antibiotic stewardship in an academic ICU was not associated with greater antibiotic de-escalation
or a reduction in the overall duration of antibiotic therapy.
Trial registration: ClinicalTrials.gov, NCT02685930. Registered on 26 January 2016.
Keywords: Pneumonia, Mechanical ventilation, Antibiotics, De-escalation

Background
Escalating rates of antibiotic resistance add substantially
to the morbidity, mortality, and costs related to infection
in hospitalized patients, especially those in the intensive
care unit (ICU) setting [1–5]. The rapid evolution of
antibiotic resistance impedes efforts to insure that initial
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appropriate antibiotic therapy (IAAT) is delivered to
critically ill infected patients. IAAT is a key determinant
of outcome in severe infection and the Surviving Sepsis
Guidelines strongly support initiatives to promote and
facilitate timely appropriate antibiotic treatment to reduce mortality [6, 7]. The rising rates of antibiotic resistance have likely contributed to the increase in mortality
attributed to antibiotic-resistant bacteria despite the
overall reduction in deaths attributed to infectious diseases in the last century [8].
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Because not all serious infections are due to multidrugresistant (MDR) organisms, clinicians must have a strategy
for determining which patients should receive empiric
broad-spectrum antibiotics [9]. The practice of antibiotic
de-escalation has emerged as an antibiotic decisionmaking strategy in the ICU balancing the need for IAAT,
in order to improve patient outcomes, with the need for
avoidance of unnecessary antibiotics so as to reduce resistance emergence [10]. De-escalation generally refers to
tailoring of empirical antibiotic treatment according to
the susceptibilities of the bacteria isolated, selecting the
narrowest spectrum antibiotic or stopping antibiotics
altogether if non-infectious etiology is established.
Given the importance of balancing IAAT with the
avoidance of unnecessary antibiotic exposure, we performed a clinical trial with the goal of determining
whether an enhanced antimicrobial de-escalation (EAD)
practice could improve antibiotic utilization and outcomes in mechanically ventilated patients with suspected
pneumonia. Our hypothesis was that introduction of an
EAD practice would increase rates of antimicrobial deescalation in the ICU population. We also wanted to
determine whether a practice of EAD impacted other
outcomes including mortality and lengths of stay.

Methods
Study population and data source

The study was conducted within the two medical ICUs
(total 34 beds). at Barnes-Jewish Hospital, an academic
referral center of 1250 beds. The medical ICUs are geographically co-located closed units with shared physician, nursing, pharmacist, and respiratory therapist staff.
The medical ICUs are staffed 24 hours per day and
7 days per week by these teams, including intensivists
board-certified in critical care. This investigation was
approved by the Washington University School of
Medicine Human Studies Committee and the need for
informed consent was waived (Institutional Review
Board (IRB)# 201509075; ClinicalTrials.gov Identifier:
NCT02685930). All mechanically ventilated patients
with suspected pneumonia, from 1 January 2016 through
31 December 2016 were eligible for inclusion. Patients
were excluded if they had a concomitant non-pulmonary
infection requiring antibiotic therapy, bronchiectasis, or
significant immune suppression. Data were prospectively
collected from the electronic health record and from
patients’ ICU teams.
Study outcomes/objectives

The primary objective of this study was to determine
whether and how frequently antibiotic de-escalation occurred following the initial prescription of antibiotics for
suspected pneumonia. The secondary outcomes assessed
included antibiotic duration, failure of initial antibiotic
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therapy, hospital mortality, ICU and hospital duration,
and subsequent infection with antibiotic-resistant strains
of bacteria.
Definitions and study design

The two medical ICUs were initially randomly assigned
so that subjects admitted to each ICU would receive either
routine antibiotic management (RAM) for suspected
pneumonia or EAD. Patients in the RAM group had all
antibiotic decisions determined by their ICU team composed of a critical care board-certified attending physician,
a critical care fellow, resident physicians, and a critical care
specialty pharmacist. Antibiotic decision-making was similar in patients in the EAD group except that all antibiotic
orders and microbiology results were reviewed on a daily
basis by the study team (TT, KF, STM, PJ, and MHK) to
specifically determine if further antibiotic de-escalation
could occur. The study team performed these reviews
from 7 a.m. to 6 p.m. on weekdays excluding weekends
and holidays. After 6 months the two medical ICUs were
crossed over in terms of the type of antibiotic management strategy delivered to patients.
Adult patients (age >18 years) were identified prospectively with suspected pneumonia (community-onset
pneumonia (COP), hospital-acquired pneumonia (HAP),
or ventilator-associated pneumonia (VAP)) in accordance
with the American Thoracic Society position statement on
pneumonia [11]. The diagnosis included presence of a
new or progressive radiographic infiltrate and at least two
of the following clinical features: fever >38 °C, leukocytosis
(>10 × 109cells/L), leukopenia (≤4 × 109cells/L), or purulent secretions. The presence of a new or progressive
radiographic infiltrate was based on the interpretation
of the chest radiograph by board-certified radiologists
blinded to the study. Patients admitted from the community without prior radiographs were assumed to
have a new infiltrate when present. Pneumonia was
classified microbiologically according to the pathogen(s)
identified as pathogen-negative, viral, antibiotic-susceptible,
or antibiotic-resistant. For purposes of this investigation,
antibiotic-susceptible was determined according to ceftriaxone susceptibility, as ceftriaxone represents the antimicrobial agent most frequently recommended for hospitalized
patients with pneumonia coming from the community setting [12]. Additionally, patients could be classified as having
non-infectious illness mimicking suspected pneumonia (see
Additional file 1: Table S1). Patients classified as having
viral pneumonia had to meet the aforementioned clinical
and radiographic criteria for pneumonia.
Early failure of initial antibiotic therapy was defined as
progression to shock, mortality, or progression of the
radiographic infiltrates without resolution of clinical parameters (leukocytosis or leukopenia, fever, purulent secretions) within 48 hours of starting antibiotic therapy.
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Septic shock was defined as the need for vasopressors
(norepinephrine, dopamine, vasopressin, epinephrine, or
phenylephrine). Only the first episode of suspected
pneumonia was recorded. Antimicrobial treatment was
classified as IAAT if the initial regimen had in vitro
activity demonstrated against the isolated pathogens.
Immune suppression was defined as acquired immune
deficiency syndrome, solid organ or bone marrow
transplant, hematologic malignancies, solid cell cancers
treated with chemotherapy or radiation, long-term corticosteroids (>10 mg/day), and other immunosuppressive
drugs (e.g., biologics for rheumatologic disorders).
Multidrug-resistant (MDR) pathogens had to demonstrate
in vitro resistance to at least one agent from three distinct
classes of antimicrobials that would normally have activity
against that bacterium [13].
Antimicrobial de-escalation was defined as a change in
the initially prescribed antibiotic regimen resulting in
one of the following: (1) a reduction in the number of
antibiotics prescribed, (2) elimination of antibiotic coverage for a class of pathogens (e.g., stopping coverage for
Staphylococcus aureus), and (3) changing the antibiotic
regimen to a more narrow-spectrum regimen. For purposes of this investigation, antibiotics were ranked according to their activity spectrum against pneumonia
pathogens, emphasizing Gram-negative bacteria (5, highest; 0, lowest) and Gram-positive bacteria (1, highest; 0,
lowest) (Table 1). For combination regimens, rank was
assigned according to the most potent drug. Therapy
escalation was defined as the switch to or addition of a
drug class or classes with a broader spectrum (using
definitions in Table 1).
Antimicrobial monitoring

From January 2002 through the present, Barnes-Jewish
Hospital utilized an antibiotic control program to help
guide antimicrobial therapy for bacterial infections. During
this time, the use of cefepime, gentamicin, or vancomycin
was unrestricted. However, initiation of intravenous ciprofloxacin, imipenem, meropenem, piperacillin/tazobactam,
Table 1 Antibiotic ranking according to activity spectrum
against Gram-negative and Gram-positive bacteria associated
with pneumonia
Gram-negative antibiotic

Rank

Gram-positive antibiotic

Rank

Carbapenem

5

Vancomycin, linezolid,
ceftaroline

1

Cefepime

4

Ureidopenicillin/monobactam

3

Quinolone (ciprofloxacin or
levofloxacin)

2

Ceftriaxone

1

None

0

None

0

ceftolozone/tazobactam, ceftazidime/avibactam, linezolid,
ceftaroline, or daptomycin was restricted and required
preauthorization from either a clinical pharmacist or
infectious diseases physician. Each intensive care unit
(ICU) had a clinical pharmacist who reviewed all antibiotic orders to ensure that dosing and interval of antibiotic administration was adequate for individual
patients based on body size, renal function, and the resuscitation status of the patient. The duration of antibiotic therapy was at the discretion of the ICU treating
team based on the patient’s microbiology results and
response to therapy.
The initial antibiotic dosages employed for the treatment of bacterial infections at Barnes-Jewish Hospital
were as follows: cefepime, 1 to 2 g every 8 hours; piperacillin–tazobactam, 4.5 g every 6 hours; imipenem, 0.5 g
every 6 hours; meropenem, 1 to 2 g every 8 hours; ceftolozone/tazobactam, 1.5 or 3 g every 8 hours; ceftazidime/
avibactam, 2.5 g every 8 hours; ciprofloxacin, 400 mg every
8 hours; levofloxacin, 750 mg once daily; vancomycin,
15 mg/kg every 12 hours; linezolid, 600 mg every 12 hours;
and ceftaroline, 600 mg every 8 hours. Subsequent
antibiotic dose and frequency were adjusted, where
appropriate.
Antimicrobial susceptibility testing

The microbiology laboratory performed antimicrobial
susceptibility of the bacterial isolates using the disk diffusion method according to guidelines and breakpoints
established by the Clinical Laboratory and Standards Institute and published during the inclusive years of the
study [14]. All classifications of antibiotic resistance were
based on in vitro susceptibility testing using these established breakpoints. Viral identification was obtained
using the Biofire FilmArray® Respiratory Panel (bioMérieux, Marcy l'Etoile, France).
Statistical analyses

The sample size was determined by a convenience sample of all mechanically ventilated patients with suspected
pneumonia identified in the medical ICUs during the
study period. Continuous variables were expressed as
mean and standard deviation (SD) or median and interquartile range (IQR) when appropriate. The t test was
used to analyze normally distributed continuous variables, whereas the Mann–Whitney U test was used to
analyze non-normally distributed continuous variables.
Categorical data were reported as frequency distributions and analyzed using the chi-square test. P values
less than 0.05 were considered statistically significant,
and all tests were two-tailed. All analyses were done
using SPSS Statistics 21 (IBM SPSS Statistics, Version
21.0. Armonk, NY, USA).
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Results
Three hundred sixty-five consecutive patients with respiratory failure and pneumonia were identified. The
main reasons for ICU admission in these patients included COP (n = 237; 64.9%), chronic obstructive pulmonary disease (n = 46; 12.6%), congestive heart failure
(n = 31; 8.5%), renal failure (n = 19; 5.2%), and altered
mental status (n = 15; 4.1%). HAP occurred in 99 patients (27.1%) and VAP in 29 patients (7.9%). Of the
365 screened patients, 82 (22.5%) were excluded due to
the presence of immune suppression, bronchiectasis, or
the presence of another non-pulmonary infection requiring antibiotic therapy (Fig. 1).
The final study population comprised 283 patients of
whom 144 (50.9%) were in the EAD group and 139
(49.1%) in the RAM group. The majority were white
men admitted from home or transferred from an outside
hospital, with approximately 10% of the patients residing
in a nursing home or rehabilitation facility before admission (Table 2). There were 100 patients (35.3%) classified
as having pathogen-negative pneumonia, 49 (17.3%) as
having viral pneumonia, 53 (18.7%) as having antibioticresistant pneumonia, 40 (14.1%) as having antibioticsusceptible pneumonia, and 41 (14.5%) as having illness
of non-infectious etiology. The distribution of pneumonia
categories was similar in both study groups (Table 3). The
pathogens identified are shown in Additional file 1: Table
S2. S. aureus (17.0%) was the most common pathogen associated with pneumonia followed by rhinovirus (12.4%),
Pseudomonas aeruginosa (9.8%), and influenza A (6.2%).
Antibiotic de-escalation occurred in 140 patients (49.5%)
including a reduction in the number of antibiotics prescribed or elimination of antibiotic coverage for a class
of pathogens in 39 patients (27.9%) and changing the
antibiotic regimen to a narrower-spectrum regimen in

101 patients (72.1%) (rank 5 or 4 Gram-negative antibiotic
changed to a rank 3, 2 or 1 Gram-negative antibiotic as
defined in Table 1 in all 101 patients). Antibiotic deescalation occurred statistically more often in patients
without septic shock compared to those with septic shock
(61.6% versus 44.6%; P = 0.001). There was no statistical
difference in antibiotic de-escalation according to double
empiric coverage for Gram-negative bacteria (n = 10)
versus single-agent coverage (n = 273) (20.2% versus
50.5%; P = 0.103). Antibiotic escalation took place in 16
patients (5.6%) due to the identification of a pathogen
resistant to the initial antibiotic regimen, and no change in
antibiotic therapy occurred in 127 (44.9%) patients.
Hospital mortality was greatest among patients undergoing antibiotic escalation (50.0%) followed by patients
having no change in antibiotic therapy (43.3%), and was
lowest for patients receiving antibiotic de-escalation
(16.4%) (P < 0.001).
Early failure of antibiotic therapy occurred in 73 patients
(25.8%) and was similar between study groups (Table 4).
Among the remaining 210 patients eligible clinically for
antimicrobial de-escalation, antibiotic de-escalation was
similar for patients in the EAD and RAM groups. There
was no difference between study groups in total antibiotic
days, hospital mortality, or hospital duration. The occurrence of secondary pneumonia and secondary pneumonia
attributed to ceftriaxone-resistant bacteria was also similar
in both groups (Table 4). Kaplan–Meier curves comparing
survival showed no difference in mortality in the RAM
group compared to the EAD group (Fig. 2).

Discussion
We found that the addition of an EAD program to a
high-intensity ICU staffing model already practicing
antimicrobial de-escalation was not associated with

Patients Screened
n=365

Excluded, n=82
-Bone Marrow Transplant (n=8)
-Lung Transplant (n=8)
-Cystic Fibrosis/Bronchiectasis (n=2)
-Neutropenic Sepsis (n=9)
-AIDS (n=11)
-Other confirmed or suspected nonpulmonary source of infection (n=52)

Enrolled
n=283

Enhanced Antimicrobial De-escalation
n=144

Routine Antibiotic Management
n=139

Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram. There were seven patients with more than one exclusion criterion
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Table 2 Baseline characteristics of the study population
Enhanced antibiotic de-escalation
(n = 144)

Routine antibiotic management
(n = 139)

P value

61 (52, 70)

60 ([45, 71)

0.494

Male

79 (54.9)

80 (57.6)

0.648

Female

65 (45.1)

59 (42.4)

Caucasian

87 (60.4)

82 (59.0)

African American

50 (34.7)

54 (38.8)

Other

Age
Gender

Race
0.523

7 (4.0)

3 (2.1)

APACHE II score

22.7 ± 7.3

21.7 ± 7.8

0.262

Charlson Comorbidity Index

2.0 (1.0, 4.8)

2.0 (1.0, 5.0)

0.744

Clinical Pulmonary Infection Score

7.2 ± 2.6

7.3 ± 2.4

0.730

Congestive heart failure

22 (15.3)

10 (14)

0.701

Chronic obstructive lung disease

42 (29.2)

41 (29.5)

0.951

Interstitial lung disease

6 (4.2)

5 (3.6)

0.804

Cirrhosis

8 (5.6)

6 (4.3)

0.631

Diabetes

41 (28.5)

48 (34.5)

0.272

End-stage renal disease

11 (7.6)

7 (5.0)

0.370

Malignancy

35 (24.3)

39 (28.1)

0.473

HIV

2 (1.4)

4 (2.9)

0.385

Solid organ transplant

5 (3.5)

4 (2.9)

0.776

Home steroids

20 (13.9)

27 (19.4)

0.211

Other home immunosuppressant

16 (11.1)

15 (10.8)

0.931

Home

58 (40.3)

46 (33.1)

0.213

Transfer from another hospital

38 (26.3)

38 (27.3)

Admission source

Transfer from lower level of care

30 (20.8)

36 (25.9)

Nursing home/skilled nursing

10 (6.9)

12 (8.6)

Lateral ICU transfer

2 (1.4)

6 (4.3)

Long-term acute care hospital

2 (1.4)

1 (0.7)

Inpatient rehabilitation facility

4 (2.8)

0 (0.0)

Within 6 months

74 (51.4)

69 (49.6)

Never or not within 6 months

70 (48.6)

70 (50.4)

Within prior 30 days

76 (52.8)

64 (46.0)

Not within prior 30 days

68 (47.2)

75 (54.0)

Prior hospitalization
0.769

Prior antibiotic exposure
0.257

Values expressed as median (interquartile range), mean ± standard deviation, or number (percent). APACHE Acute Physiology and Chronic Health Evaluation,
HIV human immune deficiency virus, ICU intensive care unit

greater antibiotic de-escalation or a reduction in the
overall duration of antibiotic therapy in patients with
suspected pneumonia during mechanical ventilation. We
also observed no significant effect on hospital mortality,
lengths of stay, or subsequent occurrence of antibioticresistant infections.

We selected antibiotic de-escalation as the primary
outcome for our investigation of an EAD program. However, as emphasized in several recent systematic reviews,
antibiotic de-escalation is dependent on multiple factors,
such as risk for infection with resistant pathogens, severity of illness, clinical response to initial therapy, site of
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Table 3 Pneumonia classification
Enhanced antibiotic Routine antibiotic P value
de-escalation
management
(n = 144)
(n = 139)
Pathogen-negative

51 (35.4)

49 (35.3)

Viral

21 (14.6)

28 (20.1)

Ceftriaxone-resistant

31 (21.5)

22 (15.8)

Ceftriaxone-sensitive

19 (13.2)

21 (15.1)

Non-infectious etiology 22 (15.3)

19 (13.7)

0.592

Values expressed as number (percent)

infection, microorganisms associated with infection,
adequacy of source control, and institutional practice
patterns [10, 15]. Moreover, antibiotic de-escalation is
accepted as a part of the global antimicrobial stewardship
approach, inclusive of other elements such as the route
and mode of antibiotic administration and the total
duration of antimicrobial therapy [15]. The problem for
intensivists is that delaying the administration of IAAT
is associated with greater mortality [6]. Therefore, as
recommended by the Surviving Sepsis Campaign, likely
pathogens associated with sepsis should initially be covered for with the empiric antibiotic regimen until microbiologic results become available [7]. This creates a
situation that often promotes the empiric administration
of broad-spectrum antibiotics. The advent of rapid diagnostics is likely to facilitate the implementation of EAD in
the future with the more timely availability of pathogen
identification and antibiotic susceptibility compared to
current approaches [10, 16].
One major area of continuing uncertainty for ICUs
implementing antimicrobial stewardship programs is the
concept of antimicrobial de-escalation. Further research
must be done to determine what defines antimicrobial
de-escalation, when it is appropriate, how to integrate
infectious disease consultation into the ICU, when to

“re-escalate” therapy, and how to transition antimicrobial decision-making when patients move from the ICU
to the hospital ward [10, 17]. At present there are no
established guidelines or benchmarks for de-escalation
practices in critically ill patients that could serve as a
reference point for ICU clinicians. Antimicrobial deescalation is also uncertain in pathogen-negative sepsis,
particularly whether it is safe to de-escalate and the optimal duration of antimicrobials. With improving culture
methods and rapid diagnostics the proportion of patients
with pathogen-negative sepsis will also likely diminish
over time, resulting in fewer such uncertainties [18]. We
chose to include patients with viral pneumonia in our
study given that viral causes of pneumonia are increasingly recognized with the advent of new rapid diagnostics and they represent an opportunity for de-escalating
traditional antibiotic therapy.
Several limitations of our study should be recognized.
First, the study design did not allow the research team
to supplant the ICU teams in terms of overall antibiotic
decision-making. The study team could only make recommendations to the ICU teams on de-escalation. Furthermore, the EAD study team was only available during
daytime hours and not during weekends or holidays.
This may have had an impact on the study team’s ability
to influence overall antibiotic management in patients
with pneumonia during the time periods the study team
was not available. Second, the EAD team and the ICU
teams comprised similar clinicians including intensivists
and pharmacists with similar levels of training and experience. This may have contributed to our inability to
detect any impact of the EAD program on antibiotic
management or clinical outcomes. Based on prior experience, inclusion of an infectious disease specialist or
microbiologist might have improved our ability to improve
antibiotic utilization with the EAD program [19, 20].
Third, we had a relatively small number of patients with

Table 4 Antibiotic and clinical outcomes
Enhanced antibiotic de-escalation
(n = 144)

Routine antibiotic management
(n = 139)

P value

Early failure of initial antibiotics

40 (27.8)

33 (23.7)

0.438

Antibiotics de-escalated*

70/104 (67.3)

70/106 (66.0)

0.845

Deterioration post de-escalation*

8/70 (11.4)

6/70 (8.6)

0.573

Total antibiotic days

7.0 (4.0, 8.8)

7.0 (4.0, 9.0)

0.616

Mortality

51 (35.4)

35 (25.2)

0.061

ICU length of stay

6.0 (3.0, 12.0)

6.0 (4.0, 12.0)

0.935

Hospital length of stay

11.0 (6.0, 22.0)

12.0 (6.0, 20)

0.918

Ventilator days

4.5 (2.0, 9.0)

4.0 (2.0, 9.0)

0.953

Secondary pneumonia

12 (8.3)

12 (8.6)

0.928

Secondary pneumonia due to antibiotic-resistant pathogen

9 (6.3)

6 (4.3)

0.468

Values expressed as median (interquartile range) and number (percent). ICU intensive care unit. *The percentages were derived from the subgroups of patients
who did not have failure of initial antibiotics

Trupka et al. Critical Care (2017) 21:180

Page 7 of 8

Cumulative Survival

programs can impact antibiotic management in other types
of ICUs which may have a lesser focus on de-escalation
practices and ICUs with different staffing models. Additionally, identifying the optimal methods for carrying out
antimicrobial de-escalation in the ICU setting, to include
the integration of infectious disease experts and rapid diagnostics, deserves further investigation. Until such studies
are performed, critical care clinicians should incorporate
antimicrobial review strategies into their daily practice in
order to balance the need for administering IAAT and the
avoidance of unnecessary antibiotic utilization.
Hospital Length of Stay (Days)

Fig. 2 Kaplan–Meier curves for cumulative survival in the routine
antibiotic management group (hatched line) and the enhanced
antimicrobial de-escalation group (solid line) (log-rank test = 0.122)

VAP compared to COP and HAP. However, most of
the patients with COP in our study had at least one
healthcare-associated risk factor (prior hospitalization,
admission from a nursing facility, immune suppression,
or prior antibiotic exposure) placing them at higher risk
for infection with potentially antibiotic-resistant bacteria.
Another limitation of our study is that the data were
derived from a single center, and this necessarily limited
the generalizability of our findings. As such, our results
may not reflect what one might see at other institutions.
For example, all of the ICUs at Barnes-Jewish Hospital
are closed units with high-intensity multidisciplinary
staffing providing continuous patient care. There is also
a long history of antimicrobial stewardship being practiced within these ICUs [21–23]. The organizational
makeup of the ICUs may also have contributed to the
negative findings of our study. The presence of highintensity staffing models in ICUs has previously been
suggested as a possible explanation for other negative
trials performed in critically ill patients [24, 25]. Moreover, our study was performed in two medical ICUs. It is
possible that our findings might have differed had we
selected other types of ICUs, due to differences in case
mix, severity of illness, and practice patterns. Last, we
did not directly integrate the use of a biomarker such
as procalcitonin into the EAD program, which might
have allowed further antimicrobial de-escalation and/or
reductions in antibiotic duration.

Conclusions
In conclusion, we found that the addition of an EAD
program to a high-intensity staffing model in medical ICUs
was not associated with greater antibiotic de-escalation or
a reduction in the overall duration of antibiotic therapy in
mechanically ventilated patients with suspected pneumonia. Future studies are needed to determine whether EAD
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